Back to BlackRock, Inc. BlackRock, Inc.

NVCTNVCT
7 quarters

Position history for BlackRock, Inc.BlackRock, Inc.'s holdings in NUVECTIS PHARMA INC

BlackRock, Inc. holds 1M shares of NVCT (NUVECTIS PHARMA INC), worth $18.4M as of 2026-Q2. The position was increased (+31.0% shares). NVCT represents 0.0% of BlackRock, Inc.'s portfolio.

Current Value

$18.4M

Current Shares

1M

Total Value Change

+$18.1M

Total Shares Change

+938,943

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1M
+31.0%
$18.4M0.0%$18.39
36
2026-Q1
Decreased
764,441
-2.4%
$5.9M0.0%$8.71
0
2025-Q4
Increased
782,805
+14.2%
$5.9M0.0%$7.38
31
2025-Q3
Increased
685,337
+6.6%
$4.1M0.0%$5.92
29
2025-Q2
Increased
642,982
+838.9%
$4.8M0.0%$7.55
43
2025-Q1
Increased
68,484
+9.8%
$669,0880.0%$10.46
18
2024-Q4
New
62,342
-
$337,2700.0%$5.14
36

Other major holders of NVCT: VANGUARD CAPITAL MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, Alyeska Investment Group, L.P.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used